Φορτώνει......
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Front Endocrinol (Lausanne) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Frontiers Media S.A.
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8221533/ https://ncbi.nlm.nih.gov/pubmed/34177807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.678797 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|